Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GEN-PROBE GENE AMPLIFICATION TUBERCULOSIS TEST PMA APPROVED BY FDA FOR CONFIRMATION OF POSITIVE AFB STAINS, ALLOWING EARLIER TREATMENT OF TB

This article was originally published in The Gray Sheet

Executive Summary

Gen-Probe plans to submit a premarket approval application supplement for use of its amplified mycobacterium tuberculosis direct (MTD) test on sputum specimens found likely to be TB-negative by acid fast bacilli (AFB) stain, the firm says. FDA approved Gen-Probe's PMA for the gene amplification test on Dec. 18 for use with positive AFB stains only. The company was seeking approval of the MTD test alone and in conjunction with positive and negative stains.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel